Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification

Thursday, 20. January 2011 07:30
Evotec AG /
Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Hamburg, Germany - 20 January 2011: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) today announced that it has entered into a collaboration with Takeda
Cambridge Limited, to identify small molecule modulators against GPCR and
Protease targets involved in various CNS and Metabolic diseases.

Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR
modeling software to identify and validate novel modulators against various
targets selected by Takeda Cambridge.

Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are proud to be
selected by Takeda Cambridge to collaborate on this important project.  We have
invested significantly in our world leading, hit-identification platform and
this alliance further validates the strength of this platform and Evotec's
ability to bring value to its partner's drug discovery efforts. We look forward
to working with Takeda Cambridge."

Dr Andrew Ayscough, Director of Chemistry at Takeda Cambridge, commented: "We
are pleased to have this opportunity to work with Evotec making use of their hit
identification platform."

No financial details are disclosed.

Contact: Dr Werner Lanthaler, Chief Executive Officer,Evotec AG, Tel.:
+49.(0)40.56081-242,  werner.lanthaler@evotec.com

Forward-Looking Statements - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. Such forward-looking statements include, but are not limited to,
statements about our expected 2010 financial results and financial growth in
2011, our anticipated financing needs, our ability to deliver on our liquidity
guidance, our belief that we are on course to sustainable profitability latest
in 2012, our expectations and assumptions concerning regulatory, clinical and
business strategies, the progress of our clinical development programmes and
timing of the commencement and results of our clinical trials, strategic
collaborations and management's plans, objectives and strategies. These
statements are neither promises nor guarantees, but are subject to a variety of
risks and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and uncertainties include,
among other things: risks that product candidates may fail in the clinic or may
not be successfully marketed or manufactured; the risk that we will not achieve
the anticipated benefits of our collaborations, partnerships and acquisitions in
the timeframes expected, or at all; risks relating to our ability to advance the
development of product candidates currently in the pipeline or in clinical
trials; our inability to further identify, develop and achieve commercial
success for new products and technologies; the risk that competing products may
be more successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial success for our
products and technologies; our inability to protect our intellectual property
and the cost of enforcing or defending our intellectual property rights; our
failure to comply with regulations relating to our products and product
candidates, including FDA requirements; the risk that the FDA may interpret the
results of our studies differently than we have; the risk that clinical trials
may not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug candidates; and
risks of new, changing and competitive technologies and regulations in the U.S.
and internationally. The list of risks above is not exhaustive. Our most recent
Annual Report on Form 20-F, filed with the Securities and Exchange Commission,
and other documents filed with, or furnished to the Securities and Exchange
Commission, contain additional factors that could impact our businesses and
financial performance. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any such statements to reflect any
change in our expectations or any change in events, conditions or circumstances
on which any such statement is based.


--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480;ISIN: DE0005664809;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


PDF of Press release:
http://hugin.info/131215/R/1480960/416334.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Evotec AG via Thomson Reuters ONE

[HUG#1480960]
Related Links: Evotec SE
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.